ZOVIRAX SWITCH DEFERRAL URGED BY CDC
This article was originally published in The Tan Sheet
Executive Summary
ZOVIRAX SWITCH DEFERRAL URGED BY CDC "until the weight of evidence indicates that its potential public health benefits outweigh the potential negative effects," Phil Pellet, PhD, National Center for Infectious Diseases, told the May 19 FDA public heating on the potential OTC use of systemic acyclovir for genital herpes.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning